The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in subjects with solid tumors.
 
Diwakar Davar
Honoraria - Array BioPharma; Immunocore; Instil Bio; Merck; Tesaro; Vedanta Biosciences
Consulting or Advisory Role - Instil Bio; Shionogi (I); Vedanta Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Apros Therapeutics; Arcus Biosciences; Ascendis Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals; Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; I-Mab (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); Molecular Templates (Inst); MT Group (Inst); NextCure (Inst); Nuvation Bio (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Incyte; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncorus (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Turning Point Therapeutics (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Alexion Pharmaceuticals; Amgen; Biogen; Bristol-Myers Squibb; Lilly; Medtronic; Merck; Pfizer; Regeneron
Research Funding - Abbvie (Inst); Agenus (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Forty Seven (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KLUS Pharma (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Odonate Therapeutics (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
John C. Krauss
Research Funding - Abbvie (Inst); Abbvie (Inst); ACCRU (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Cardiff Oncology; Daiichi Sankyo/Arqule (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Isofol Medical (Inst); Novartis (Inst); NSABP FOUNDATION (Inst); NSABP Foundation (Inst); Pfizer (Inst); Tempest Therapeutics (Inst); Tempest Therapeutics (Inst)
 
Robert Stagg
Employment - Tempest Therapeutics
Stock and Other Ownership Interests - Tempest Therapeutics
 
Brian Francica
Employment - Tempest Therapeutics
Stock and Other Ownership Interests - Tempest Therapeutics
 
Anne Moon
Employment - Tempest Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; Chinook Therapeutics; Cytokinetics; Johnson & Johnson; Merck; Pfizer; Tempest Therapeutics
 
Yonchu Jenkins
Employment - Abalone Biosciences (I); Calithera Biosciences; Second Genome (I); Tempest Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Johnson & Johnson/Janssen (I); Novartis (I); Seagen (I); Vertex (I)
Consulting or Advisory Role - Calithera Biosciences; Xoma (I)
 
Peppi Prasit
Employment - Tempest Therapeutics
Leadership - AM Sciences; Genesis Therapeutics
Stock and Other Ownership Interests - AM Sciences; Genesis Therapeutics; Tempest Therapeutics
Honoraria - Genesis Therapeutics; Glycosyn; Shouti; Tempest Therapeutics
Consulting or Advisory Role - Genesis Therapeutics; Glycosyn; Shouti; Tempest Therapeutics
Patents, Royalties, Other Intellectual Property - Inception Sciences; Tempest Therapeutics
 
Thomas Walter Dubensky
Employment - Tempest Therapeutics
Leadership - Tempest Therapeutics
Stock and Other Ownership Interests - Tempest Therapeutics; Tempest Therapeutics; Tempest Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - Avidea Technologies; Oncorus
Patents, Royalties, Other Intellectual Property - Multiple issued (ca. 40) and pending patents, all of which have been assigned to the various companies which own the rights to them (e.g., Novartis, Chinook, Tempest). I receive no royalties from any of these patents.
 
Sam H. Whiting
Employment - Calithera Biosciences; Recludix Pharma (I); Seagen (I); Tempest Therapeutics
Leadership - Recludix Pharma (I); Tempest Therapeutics
Stock and Other Ownership Interests - Recludix Pharma (I); Tempest Therapeutics
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)